---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024143"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:14:24.527654+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Finch Q3 net loss $40.4M on $18.1M goodwill impairment; PRISM4 Phase 3 dosing ongoing

## Summary
- Net loss $40.4M vs $10.0M in Q3 2021 due to $18.1M goodwill impairment and $11.2M revenue decline from Takeda termination.
- Cash and equivalents $85.3M at Sept. 30, 2022; expected runway into Q2 2024, including sublease inflows.
- Patient dosing underway in PRISM4 Phase 3 trial of CP101 for recurrent C. diff; topline data anticipated H1 2024.
- Howard Franklin appointed Chief Medical Officer; ASD program (FIN-211) suspended; exploring partnerships for IBD candidates.

## SEC filing metadata
- accession: 0000950170-22-024143
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017022024143/0000950170-22-024143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017022024143/fnch-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024143
- JSON: https://secwatch.observer/filing/0000950170-22-024143.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024143.txt

## Key facts
- Earnings Releases
  Finch Therapeutics Group, Inc. reported third quarter ended September 30, 2022 results: revenue $11.2 million, net income ($40.4 million).
  - Period: third quarter ended September 30, 2022
  - Revenue: $11.2 million
  - Net income: ($40.4 million)
  - Result: reported results
  source text: net loss was driven by a charge of $18.1 million for the full impairment of the Company’s goodwill during the current quarter. Additionally, there was a decrease in revenue of $11.2 million due to changes under Finch’s collaboration agreement with Takeda, including Takeda’s election in August 2022 to terminate the agreement. Finch also reported an increase in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000095017022024143/0000950170-22-024143-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.